Statistiche di base
| LEI | YA13X31F3V31L8TMPR58 |
| CIK | 1099800 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Edwards Lifesciences Corporation
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Comm |
|
| August 19, 2025 |
EDWARDS LIFESCIENCES ANNOUNCES $500 MILLION ACCELERATED SHARE REPURCHASE EXHIBIT 99.1 Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 www.edwards.com Media Contact: Amy Meshulam, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES ANNOUNCES $500 MILLION ACCELERATED SHARE REPURCHASE IRVINE, Calif., Aug. 19, 2025 – Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated sh |
|
| August 6, 2025 |
Calculation of Filing Fee Tables S-8 Edwards Lifesciences Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value of $1. |
|
| August 6, 2025 |
EDWARDS LIFESCIENCES COMMENTS ON FTC’S ACTION TO BLOCK PROPOSED ACQUISITION OF JENAVALVE EXHIBIT 99.1 Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com Media Contact: Amy Meshulam, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES COMMENTS ON FTC’S ACTION TO BLOCK PROPOSED ACQUISITION OF JENAVALVE IRVINE, CA – August 6, 2025 – Edwards Lifesciences (NYSE: EW) announced today that t |
|
| August 6, 2025 |
Calculation of Filing Fee Tables S-8 Edwards Lifesciences Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value of $1. |
|
| August 6, 2025 |
Exhibit 10.2 Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For International Employees (As Amended and Restated February 13, 2025) Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For International Employees (As Amended and Restated February 13, 2025) ARTICLE I - PURPOSE 1.01. Purpose The Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for |
|
| August 6, 2025 |
Exhibit 10.1 Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For United States Employees (As Amended and Restated February 13, 2025) Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For United States Employees (As Amended and Restated February 13, 2025) ARTICLE I - PURPOSE 1.01. Purpose The Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 S-8 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFES |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 21, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 24, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 24, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 24, 2025 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 21, 2025 |
As filed with the Securities and Exchange Commission on July 21, 2025 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2025 Registration No. |
|
| July 21, 2025 |
Calculation of Filing Fee Tables S-3 Edwards Lifesciences Corp Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $1. |
|
| July 21, 2025 |
Form T-1 Statement of Eligibility under Trust Indenture Act of 1939 of Trustee under the Indenture EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 36-4316614 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) One Edwards Way, Irvine, California 92614 (Address of Principal Executive O |
|
| May 30, 2025 |
Conflict Minerals Report as contemplated by Item 1.02 of this Form. Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2024 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinician |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commissi |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFE |
|
| April 23, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| April 23, 2025 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| April 14, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 26, 2025 |
ewnaa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 28, 2025 |
Edwards Lifesciences Corporation's Insider Trading Policy EDWARDS LIFESCIENCES CORPORATION Insider Trading Policy Exhibit 19.1 N Table of Contents I PURPOSE 3 II APPLICABILITY 3 1. Effective Date 3 2. Covered Persons 3 3. Securities 3 4. Material Nonpublic Information 4 5. Post-Termination Obligations 5 III. PENALTIES AND LIABILITY 5 IV. RESTRICTIONS ON TRADING 5 1. Prohibited Transactions 5 2. Exemptions 6 3. Tipping 7 4. Other Prohibited Transactions 7 |
|
| February 28, 2025 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2024: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences LLC Delaware U.S. Edwards Lifesciences Holding, Inc. D |
|
| February 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2025 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Co |
|
| February 11, 2025 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| November 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Edwards Lifesciences Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28176E108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Edwards Lifesciences Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions o |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS |
|
| October 24, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| October 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 24, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| September 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 3, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Co |
|
| September 3, 2024 |
EDWARDS LIFESCIENCES COMPLETES SALE OF CRITICAL CARE Company announces $1 billion share repurchase Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 31, 2024 |
Exhibit 10.1 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (as Amended and Restated on February 22, 2024) Table of Contents Article 1. Establishment, Objectives, and Duration 1 Article 2. Definitions 1 Article 3. Administration 4 Article 4. Eligibility and Participation 4 Article 5. Shares Subject to the Program and Maximum Awards 4 Article 6. Stock Options 6 Arti |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFES |
|
| July 31, 2024 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Edwards Lifesciences Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value of $1. |
|
| July 31, 2024 |
Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program EXHIBIT 4 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (as Amended and Restated on February 22, 2024) Table of Contents Article 1. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) One Edwards Way Irvine, California 92614 (Address, includi |
|
| July 24, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 24, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 24, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 15, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 10, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| June 3, 2024 |
EX-99.1 Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES TO SELL CRITICAL CARE TO BD Agreement strengthens Edwards’ strategy to advance structural heart innovation IRVINE, CA, June 3, 2024 – |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commiss |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 (State or other jurisdiction of incorporation) (Commission file number) One Edwards Way, Irvine, California 92614 (Address of principal executive offices) (Zip code) Arnold A. Pinkston |
|
| May 30, 2024 |
Conflict Minerals Report as contemplated by Item 1.02 of this Form. Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2023 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Sustainability reflects the impact we are having on society and our stake |
|
| May 8, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commissi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFE |
|
| April 29, 2024 |
Exhibit 10.1 Spinoff Change in Control Agreement THIS SPINOFF CHANGE IN CONTROL AGREEMENT is made, entered into, and is effective as of March 15, 2024 (hereinafter referred to as the “Effective Date”), by and between EDWARDS LIFESCIENCES CORPORATION, a Delaware corporation, and Catherine Szyman (the “Executive”). WHEREAS, the Executive is currently employed by the Company in a key management capac |
|
| April 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| April 25, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| March 26, 2024 |
Edwards Lifesciences 2023 Annual ReportEdwards Life esciences is the global leader in patient-focused medical inn novations for structural heart disease and critical care mon nitoring. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 26, 2024 |
Edwards Lifesciences 2023 Annual Report Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. |
|
| February 13, 2024 |
EW / Edwards Lifesciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0818-edwardslifesciencesco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Edwards Lifesciences Corp Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 12, 2024 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2023: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences LLC Delaware U.S. Edwards Lifesciences Services GmbH G |
|
| February 12, 2024 |
Edwards Lifesciences Corporation Form of Employment Agreement Exhibit 10.3 Edwards Lifesciences LLC One Edwards Way, Irvine, CA USA 92614 Phone: 949.250.2500, Fax: 949.250.2525 www.edwards.com Employment Agreement NOTICE TO EMPLOYEE: BEFORE SIGNING, PLEASE READ THE FOLLOWING AGREEMENT IN ITS ENTIRETY, MAKE CERTAIN THAT YOU UNDERSTAND IT, AND, IF DESIRED, REVIEW IT WITH YOUR ATTORNEYS AND ADVISORS. THIS EMPLOYMENT AGREEMENT (the “Agreement”) is executed by an |
|
| February 12, 2024 |
Edwards Lifesciences Corporation's Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 EDWARDS LIFESCIENCES CORPORATION Policy for Recovery of Erroneously Awarded Compensation This Policy for Recovery of Erroneously Awarded Compensation (the “Policy”) has been adopted by the Compensation and Governance Committee (the Committee”) of the Board of Directors (the “Board”) of Edwards Lifesciences Corporation (the “Company”) on October 31, 2023. Capitalized terms used in this |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 6, 2024 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| February 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| December 7, 2023 |
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS |
|
| October 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2023 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1 |
|
| July 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 26, 2023 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 (State or Other Jurisdiction of Incorporation) (Commission File No.) One Edwards Way, Irvine, California 92614 (Address of Principal Executive Offices) (Zip Code) Arnold A. Pinkston (949) 2 |
|
| June 1, 2023 |
Conflict Minerals Report as contemplated by Item 1.02 of this Form. Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2022 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Sustainability reflects the impact we are having on society and our stake |
|
| May 15, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDWARDS LIFESCIENCES CORPORATION Pursuant to Section 242 of the General Corporation Law of the State of Delaware Edwards Lifesciences Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. Th |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1- |
|
| April 26, 2023 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| March 28, 2023 |
ewnaaproof1 Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 28, 2023 |
Edwards Lifesciences 2022 Annual ReportEd w ard s Lifescien ces n 2 02 2 A n n u al R ep o rt Information on the Internet Investor Information Corporate Public Relations Transfer Agent Independent Registered Public Accounting Firm . |
|
| March 28, 2023 |
a2023proxysupplement-sto Edwards Lifesciences Spring 2023 Stockholder Engagement Cautionary Statement and Use of Non-GAAP Financial Measures 2 This presentation may include forward-looking statements, including, but not limited to, financial forecasts, that involve risks and uncertainties that could cause actual results or experience to differ materially from historical results or those anticipated. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 21, 2023 |
EX-3.1 Exhibit 3.1 EDWARDS LIFESCIENCES CORPORATION BYLAWS (Amended and Restated as of February 16, 2023) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF HOLDING MEETINGS. All meetings of the stockholders shall be held at the principal executive offices of the Corporation, or such other place, if any, as shall be determined by the Board of Directors. SECTION 2. ELECTION OF DIRECTORS. (a) The annual mee |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (C |
|
| February 13, 2023 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2022: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences LLC Delaware U.S. Edwards Lifesciences (U.S.) Inc. Del |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 9, 2023 |
EW / Edwards Lifesciences Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Edwards Lifesciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2023 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| January 31, 2023 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| December 8, 2022 |
EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949.250.2500 ? Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN IRVINE, Calif., Dec. 8, 2022 ? Edwards Lifesciences Corporation (NYSE: EW) today announced that |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Co |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| November 1, 2022 |
EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE EX-99.1 Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE IRVINE, Calif., Nov. 1, 2022 — Edwards Lifesciences (NYSE: EW) today announced that |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 28, 2022 |
CORRESP 1 filename1.htm October 28, 2022 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, D.C. 20549 Attn: Amanda Ravitz Barbara Jacobs RE: Edwards Lifesciences Corp Definitive Proxy Statement on Schedule 14A Filed March 22, 2022 File No. 001-15525 Dear Mses. Ravitz and Jacobs, On behalf of Edwards Lifesciences Corporation |
|
| October 27, 2022 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| October 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1 |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 28, 2022 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| July 22, 2022 |
Form T-1 Statement of Eligibility under Trust Indenture Act of 1939 of Trustee under the Indenture Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) N |
|
| July 22, 2022 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 EDWARDS LIFESCIENCES CORPORATION Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $1. |
|
| July 22, 2022 |
Power of Attorney (included on signature page hereto) Table of Contents As filed with the Securities and Exchange Commission on July 21, 2022 Registration No. |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| July 21, 2022 |
Exhibit 10.1 Execution Version Published CUSIP Numbers: Deal: 28176FAP0 Facility: 28176FAQ8 Yen Sub-Facility: 28176FAS4 Singapore Dollar Sub-Facility: 28176FAR6 FIVE YEAR CREDIT AGREEMENT dated as of July 15, 2022 among EDWARDS LIFESCIENCES CORPORATION, as a Borrower CERTAIN SUBSIDIARIES, as Borrowers BANK OF AMERICA, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., as Syndication Agent MO |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K 11-K 1 ew11-k2021usplan.htm 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| May 31, 2022 |
Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2021 EX-1.01 2 d360802dex101.htm EX-1.01 Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2021 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. This conflict minerals report (this “ |
|
| May 31, 2022 |
SD 1 d360802dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 (State or Other Jurisdiction of Incorporation) (Commission File No.) One Edwards Way, Irvine, California 92614 (Address of Principal Executive Offices) (Zip Code) Arn |
|
| May 4, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commiss |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1- |
|
| April 26, 2022 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| April 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| March 22, 2022 |
DEFA14A 1 d316506ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 22, 2022 |
DEFA14A 1 d322528ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 22, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 14, 2022 |
Exhibit 10.17 Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program Restricted Stock Units Agreement You have been selected to be a Participant in the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program (the ?Program?), as specified below: Participant: Date of Grant: Number of Restricted Stock Units Granted: Vesting Date: The Restricted |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 14, 2022 |
Exhibit 10.13 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program Global Performance-Based Restricted Stock Unit Award Agreement THIS AGREEMENT, including any appendix for the Participant?s country (the ?Appendix?) and the Performance-Based Restricted Stock Unit Statement attached to the front of this agreement (the ?Statement?), sets forth the terms and conditions of t |
|
| February 14, 2022 |
Exhibit 10.16 Name: Date of Grant: Option Price Date of Expiration: Number of Shares Covered: Vesting Schedule This certifies that on , Edwards Lifesciences Corporation granted to the Participant shown above a Nonqualified Stock Option to purchase shares of its common stock as indicated above upon the terms and conditions of the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Inc |
|
| February 14, 2022 |
Exhibit 10.12 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program Global Restricted Stock Unit Award Agreement THIS AGREEMENT, including any appendix for the Participant?s country (the ?Non-U.S. Countries Additional Terms Appendix?), the appendix containing additional defined terms related to a change in control (the ?Additional Defined Terms Appendix? and, together wit |
|
| February 14, 2022 |
Exhibit 10.18 Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program Restricted Stock Agreement You have been selected to be a Participant in the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program (the ?Program?), as specified below: Participant: Date of Grant: Number of Shares of Restricted Stock Granted: Lapse of Restrictions Dates: R |
|
| February 14, 2022 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK References to ?we,? ?us? and ?our? refer to Edwards Lifesciences Corporation. General This section summarizes the rights of our capital stock, certain provisions of our amended and restated certificate of incorporation, as amended (our ?certificate of incorporation?), and our bylaws, as amended and restated (our ?bylaws?), and certain provisions of applicab |
|
| February 14, 2022 |
Exhibit 10.15 2020 Nonemployee Directors Stock Incentive Program Edwards Lifesciences Corporation (as amended and restated November 18, 2021) Table of Contents Article 1. Establishment, Objectives, and Duration 1 Article 2. Definitions 1 Article 3. Administration 3 Article 4. Eligibility and Participation 4 Article 5. Shares Subject to the Program 4 Article 6. Stock Options 5 Article 7. Stock Issu |
|
| February 14, 2022 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2021: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences LLC Delaware U.S. Edwards Lifesciences (U.S.) Inc. Del |
|
| February 14, 2022 |
Exhibit 10.11 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program Global Nonqualified Stock Option Award Agreement THIS AGREEMENT, including any appendix for the Participant?s country (the ?Non-U.S. Countries Additional Terms Appendix?), the appendix containing additional defined terms (the ?Additional Defined Terms Appendix? and, together with the Non-U.S. Countries Ad |
|
| February 9, 2022 |
EW / Edwards Lifesciences Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Edwards Lifesciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 26, 2022 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 26, 2022 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 27, 2021 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1 |
|
| July 29, 2021 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 15, 2021 |
Exhibit 3.1 EDWARDS LIFESCIENCES CORPORATION BYLAWS (Amended and Restated as of July 15, 2021) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF HOLDING MEETINGS. All meetings of the stockholders shall be held at the principal executive offices of the Corporation, or such other place, if any, as shall be determined by the Board of Directors. SECTION 2. ELECTION OF DIRECTORS. (a) The annual meeting of sto |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 36-4316614 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) One Edwards Way, Irvine, California 92614 (Address of Principal Execu |
|
| May 28, 2021 |
Conflict Minerals Report as contemplated by Item 1.02 of this Form. Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2020 OVERVIEW Edwards Lifesciences Corporation (?Edwards,? and also referred to as ?we,? ?us,? or ?our?) is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. This conflict minerals report (this ?Report?) relates to the process unde |
|
| May 7, 2021 |
As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. |
|
| May 7, 2021 |
S-8 1 d264030ds8.htm S-8 As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (State or other jurisdiction of incorpor |
|
| May 5, 2021 |
Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ?92614 Phone: 949.250.2500 ? Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS ANNOUNCES UPDATES FROM ANNUAL MEETING Board Authorizes Additional $1 Billion for Share Repurchase Program IRVINE, Calif., May 5, 2020 ? Edwa |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commiss |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1- |
|
| April 28, 2021 |
Exhibit 10.1 Description of Severance Benefits for Mr. Jean-Luc Lemercier Mr. Jean-Luc Lemercier, one of the named executive officers of Edwards Lifesciences Corporation (the ?Company?), is eligible to receive severance benefits if his employment is terminated by the Company for any reason other than for cause. These benefits will consist of cash severance equal to one month of his monthly base sa |
|
| April 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| April 20, 2021 |
Edwards Lifesciences Corporation One Edwards Way ? Irvine, CA USA ? 92614 Phone: 949. |
|
| March 23, 2021 |
DEFA14A 1 d93598ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| March 23, 2021 |
DEF 14A 1 d107323ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 12, 2021 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK References to ?we,? ?us? and ?our? refer to Edwards Lifesciences Corporation. General This section summarizes the rights of our capital stock, certain provisions of our amended and restated certificate of incorporation, as amended (our ?certificate of incorporation?), and our bylaws, as amended and restated (our ?bylaws?), and certain provisions of applicab |
|
| February 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 12, 2021 |
Exhibit 10.17 Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program Restricted Stock Units Agreement You have been selected to be a Participant in the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program (the ?Program?), as specified below: Participant: Date of Grant: Number of Restricted Stock Units Granted: Vesting Date: The Restricted Stock Uni |
|
| February 12, 2021 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2020: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences LLC Delaware U.S. Edwards Lifesciences SAS France Edwa |
|
| February 12, 2021 |
Exhibit 10.16 Participant Stock Option Statement Name: Date of Grant: Option Price: Date of Expiration: Number of Shares Covered: Vesting Schedule This certifies that on , Edwards Lifesciences Corporation granted to the Participant shown above a Nonqualified Stock Option to purchase shares of its common stock as indicated above upon the terms and conditions of the Nonemployee Directors Stock Incen |
|
| February 12, 2021 |
EX-10.18 5 ex-101810xkq42020.htm EX-10.18 Exhibit 10.18 Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program Restricted Stock Agreement You have been selected to be a Participant in the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program (the “Program”), as specified below: Participant: Date of Grant: Number of Shares of Restricted Stock Granted |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Edwards Lifesciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 27, 2021 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| January 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2021 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 26, 2020 |
Exhibit 10.1 AMENDMENT NO. 5 TO THE EDWARDS LIFESCIENCES TECHNOLOGY SARL RETIREMENT SAVINGS PLAN The Edwards Lifesciences Technology Sarl Retirement Savings Plan (the “Plan”) effective January 1, 2011, as amended by Amendment No. 1 executed on June 25, 2013, Amendment No. 2 executed on February 24, 2017, Amendments No. 3 executed on February 14, 2018, and Amendment No, 4 executed on November 4, 20 |
|
| October 26, 2020 |
Exhibit 10.2 Amendment No. 12 to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan (Effective January 1, 2020) The Edwards Lifesciences Corporation 401(k) Savings and Investment Plan ("Plan") as amended and restated as of January 1, 2016 as amended by Amendment No. 1 executed on May 2, 2016, Amendment No. 2 executed on December 19, 2016, Amendment No.3 executed on February 24 |
|
| October 22, 2020 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| October 22, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| July 27, 2020 |
Exhibit 10.3 EDWARDS LIFESCIENCES CORPORATION 2001 EMPLOYEE STOCK PURCHASE PLAN FOR UNITED STATES EMPLOYEES (As Amended and Restated May 7, 2020) 326980.1 Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For United States Employees (As Amended and Restated May 7, 2020) ARTICLE I - PURPOSE 1.01. Purpose The Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for Uni |
|
| July 27, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1 |
|
| July 27, 2020 |
Exhibit 10.1 Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (as Amended and Restated May 7, 2020) Table of Contents Article 1. Establishment, Objectives, and Duration 1 Article 2. Definitions 1 Article 3. Administration 4 Article 4. Eligibility and Participation 4 Article 5. Shares Subject to the Program and Maximum Awards 5 Article 6. Stock Options 6 Article 7. Re |
|
| July 27, 2020 |
Exhibit 10.4 EDWARDS LIFESCIENCES CORPORATION 2001 EMPLOYEE STOCK PURCHASE PLAN FOR INTERNATIONAL EMPLOYEES (As Amended and Restated May 7, 2020) Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan For International Employees (As Amended and Restated May 7, 2020)1 ARTICLE I - PURPOSE 1.01. Purpose The Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for Internation |
|
| July 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 23, 2020 |
EX-99.1 2 ex-991q22020.htm EXHIBIT 99.1 Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS IRVINE, Calif., July 23, 2020 — Edwards Lifesciences Corporation (NY |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 15, 2020 |
PAUL LAVIOLETTE APPOINTED TO EDWARDS LIFESCIENCES BOARD OF DIRECTORS EX-99.1 Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way • Irvine, CA USA • 92614 Phone: 949.250.2500 • Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 PAUL LAVIOLETTE APPOINTED TO EDWARDS LIFESCIENCES BOARD OF DIRECTORS IRVINE, Calif., July 15, 2020 – Edwards Lifesciences Corporation (NYSE |
|
| July 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 13, 2020 |
EDWARDS LIFESCIENCES AGREES TO GLOBAL TRANSCATHETER LITIGATION SETTLEMENT WITH ABBOTT EX-99.1 Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES AGREES TO GLOBAL TRANSCATHETER LITIGATION SETTLEMENT WITH ABBOTT IRVINE, Calif., July 13, 2020 – Edwards Lifesciences Corpor |
|
| June 16, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| June 16, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 36-4316614 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) One Edwards Way, Irvine, California 92614 (Address of Principal Execu |
|
| May 29, 2020 |
Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2019 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2019 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. |
|
| May 8, 2020 |
EX-99.1 Exhibit 99.1 Edwards Lifesciences Corporation One Edwards Way • Irvine, CA USA • 92614 Phone: 949.250.2500 • Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS ANNOUNCES UPDATES FROM ANNUAL MEETING Stockholders Approve Board Recommendations, Including Stock Split IRVINE, Calif., May 7, 2020 |
|
| May 8, 2020 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation (the “Corporation”), a corporation organized and existing under the laws of the state of Delaware (the “DGCL”), does hereby certify that: 1. The name under which the Corporation was originally incorporated was CVG Controlled Inc. and |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commiss |
|
| April 28, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1- |
|
| April 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| April 23, 2020 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| April 13, 2020 |
EW / Edwards Lifesciences Corp. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 25, 2020 |
EW / Edwards Lifesciences Corp. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 25, 2020 |
EW / Edwards Lifesciences Corp. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 25, 2020 |
Definitive Proxy Statement filed on March 25, 2020 DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2020 |
EW / Edwards Lifesciences Corp. PRE 14A - - PRE 14A PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 14, 2020 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following is a list of subsidiaries of Edwards Lifesciences Corporation, omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2019: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences Innovation Holding LLC Delaware U.S. Edwards Lifescien |
|
| February 14, 2020 |
Description of Edwards Lifesciences Corporation's Capital Stock EX-4.1 2 ex-4210xkq42019.htm EXHIBIT 4.1 Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK References to “we,” “us” and “our” refer to Edwards Lifesciences Corporation. General This section summarizes the rights of our capital stock, certain provisions of our amended and restated certificate of incorporation (our “certificate of incorporation”) and our bylaws, as amended and restated (our “bylaws”), and ce |
|
| February 12, 2020 |
EW / Edwards Lifesciences Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Edwards Lifesciences Corp Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 30, 2020 |
EX-99.1 2 ex-991q42019.htm EXHIBIT 99.1 Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS IRVINE, Calif., January 30, 2020 — Edwards Lifesciences Corporation |
|
| January 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2020 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 23, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 23, 2019 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| July 26, 2019 |
EW / Edwards Lifesciences Corp. S-3ASR - - FORM S-3ASR Form S-3ASR As filed with the Securities and Exchange Commission on July 26, 2019 Registration No. |
|
| July 26, 2019 |
Form T-1 Statement of Eligibility under Trust Indenture Act of 1939 of Trustee under the Indenture EX-25.1 4 d758499dex251.htm EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b) (2) WELLS FARGO BANK, NATIONAL ASSOCIATION (Exact name of trustee as spe |
|
| July 26, 2019 |
Amendment No. 11 to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan Exhibit 10.1 Amendment No. 11 to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan (Effective January 1, 2016) The Edwards Lifesciences Corporation 401(k) Savings and Investment Plan ("Plan") as amended and restated as of January 1, 2016 (“Plan”), as amended by Amendment No. 1 executed on May 2, 2016, Amendment No. 2 executed on December 19, 2016, Amendment No. 3 executed on |
|
| July 26, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1 |
|
| July 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commis |
|
| July 23, 2019 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| June 14, 2019 |
EW / Edwards Lifesciences Corp. 11-K - - 11-K 11-K 1 ew11-k2018puertoricoplan.htm 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C |
|
| June 14, 2019 |
EW / Edwards Lifesciences Corp. 11-K - - 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 A. Full tit |
|
| May 31, 2019 |
Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2018 EX-1.01 2 d20176dex101.htm EX-1.01 Exhibit 1.01 Edwards Lifesciences Corporation Conflict Minerals Report For the Year Ended December 31, 2018 OVERVIEW Edwards Lifesciences Corporation (“Edwards,” and also referred to as “we,” “us,” or “our”) is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. This conflict minerals report (this “R |
|
| May 31, 2019 |
EW / Edwards Lifesciences Corp. SD - - SD SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT EDWARDS LIFESCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 1-15525 36-4316614 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) One Edwards Way, Irvine, California 92614 (Address of Principal Ex |
|
| May 8, 2019 |
Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Comm |
|
| April 26, 2019 |
Exhibit 10.1 Amendment No. 10 to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan (Effective January 1, 2016) The Edwards Lifesciences Corporation 401(k) Savings and Investment Plan ("Plan") as amended and restated as of January 1, 2016 (“Plan”), as amended by Amendment No. 1 executed on May 2, 2016, Amendment No. 2 executed on December 19, 2016, Amendment No. 3 executed on |
|
| April 26, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1- |
|
| April 23, 2019 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| April 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commi |
|
| March 27, 2019 |
EW / Edwards Lifesciences Corp. DEFA14A DEFA14A 1 d719426ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 27, 2019 |
EW / Edwards Lifesciences Corp. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 27, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2019 |
Subsidiaries of Edwards Lifesciences Corporation Exhibit 21.1 The following entities are wholly-owned subsidiaries of Edwards Lifesciences Corporation: Legal Entity State of Incorporation/ Formation Country of Incorporation/ Formation Edwards Lifesciences Asset Management Corporation Delaware U.S. Edwards Lifesciences CardiAQ LLC Delaware U.S. Edwards Lifesciences Corporation of Puerto Rico Delaware U.S. Edwards Lifesciences Financing LLC Delawa |
|
| February 15, 2019 |
Exhibit 10.26 AMENDMENT NO. 4 TO THE EDWARDS LIFESCIENCES TECHNOLOGY SARL RETIREMENT SAVINGS PLAN The Edwards Lifesciences Technology Sarl Retirement Savings Plan (the “Plan”) effective January 1, 2011, as amended by Amendment No. 1 executed on June 25, 2013, Amendment No. 2 executed on February 24, 2017, and Amendment No. 3 executed on February 14, 2018, is hereby further amended as described bel |
|
| February 15, 2019 |
Exhibit 10.7 Edwards Lifesciences United States 2018 Edwards Incentive Plan (EIP) 1 PLAN OBJECTIVE The Edwards Lifesciences Incentive Plan for 2018 (“2018 EIP” or “the Plan”) is a discretionary annual cash bonus program designed to motivate eligible participants to contribute to the achievement of the financial and strategic objectives of Edwards Lifesciences LLC (“Edwards” or “the Company”), as w |
|
| February 15, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 |
|
| February 11, 2019 |
EW / Edwards Lifesciences Corp. / VANGUARD GROUP INC Passive Investment edwardslifesciencescorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8 )* Name of issuer: Edwards Lifesciences Corp Title of Class of Securities: Common Stock CUSIP Number: 28176E108 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the ap |
|
| January 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| January 31, 2019 |
Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949. |
|
| January 15, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2019 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) |
|
| January 15, 2019 |
EX-99.1 2 d689431dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Boston Scientific contacts: Media Relations: Trish Backes, 651-582-5887 Investor Relations: Susie Lisa, CFA, 508-683-5565 Edwards Lifesciences contacts: Media Relations: Sarah Huoh, 949-250-5070 Investor Relations: David K. Erickson, 949-250-6826 BOSTON SCIENTIFIC, EDWARDS LIFESCIENCES AGREE TO GLOBAL LITIGATION SETTLEMENT All |
|
| October 26, 2018 |
EW / Edwards Lifesciences Corp. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 26, 2018 |
Exhibit 10.1 Amendment No. 9 to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan (restated effective January 1, 2016) The Edwards Lifesciences Corporation 401(k) Savings and Investment Plan ("Plan") as amended and restated as of January 1, 2016 (“Plan”), as amended by Amendment No. 1 executed on May 2, 2016, Amendment No. 2 executed on December 19, 2016, Amendment No. 3 exec |
|
| October 23, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 23, 2018 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Com |
|
| October 23, 2018 |
EX-99.1 2 ex-991q32018.htm EXHIBIT 99.1 Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: David K. Erickson, 949-250-6826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, Calif., October 23, 2018 — Edwards Lifesciences Corporation |
